Protein-based vaccine as the booster dose for adults: evidence and beyond
- PMID: 35963271
- PMCID: PMC9365310
- DOI: 10.1016/S1473-3099(22)00447-9
Protein-based vaccine as the booster dose for adults: evidence and beyond
Conflict of interest statement
We declare no competing interests.
Comment on
-
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.Lancet Infect Dis. 2022 Nov;22(11):1565-1576. doi: 10.1016/S1473-3099(22)00420-0. Epub 2022 Aug 10. Lancet Infect Dis. 2022. PMID: 35963274 Free PMC article. Clinical Trial.
References
-
- WHO WHO coronavirus (COVID-19) dashboard. 2022. https://covid19.who.int
-
- Stuart ASV, Shaw RH, Liu X, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet. 2022;399:36–49. - PMC - PubMed
-
- Maxmen A. The fight to manufacture COVID vaccines in lower-income countries. Nature. 2021;597:455–457. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
